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Although many studies have described patient-level risk factors for outcomes in heart failure
(HF), health care structural determinants remain largely unexplored. This research reports
patient-, hospital- and country-level characteristics associated with 1-year all-cause mortal-
ity among patients with chronic HF, and investigates geographic and hospital variation in
mortality.
Methods and findings
We included 9,277 patients with chronic HF enrolled between May 2011 and November
2017 in the prospective cohort study European Society of Cardiology Heart Failure Long
Term registry across 142 hospitals, located in 22 countries. Mean age of the selected outpa-
tients was 65 years (sd 13.2) and 28% were female. The all-cause 1-year mortality rate per
100 person-years was 7.1 (95% confidence interval (CI) 6.6–7.7), and varied between coun-
tries (median 6.8, IQR 5.6–11.2) and hospitals (median 7.8, IQR 5.2–12.4). Mortality was
associated with age (incidence rate ratio 1.03, 95% CI 1.02–1.04), diabetes mellitus (1.37,
1.15–1.63), peripheral artery disease (1.56, 1.27–1.92), New York Heart Association class
III/IV (1.91, 1.60–2.30), treatment with angiotensin-converting enzyme inhibitor and angio-
tensin receptor antagonists (0.71, 0.57–0.87) and HF clinic (0.64, 0.46–0.89). No other hos-
pital-level characteristics, and no country-level healthcare characteristics were associated
with 1-year mortality, with case-mix standardised variance between countries being very
low (1.83e-06) and higher for hospitals (0.372).
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Conclusions
All-cause mortality at 1 year among outpatients with chronic HF varies between countries
and hospitals, and is associated with patient characteristics and the availability of hospital
HF clinics. After full adjustment for clinical, hospital and country variables, between-country
variance was negligible while between-hospital variance was evident.
Introduction
Heart failure (HF) is characterized by a high rate of hospital admissions and death, significant
functional compromise, reduced quality of life, and increased caregiver burden [1,2]. Remark-
able progress in the treatment of HF has been made in the last few decades and included in the
current International guidelines [3,4], with an improvement in survival of patients with
chronic HF [5,6]. Several evidence-based trials have identified effective medical treatments for
patients with HF and reduced ejection fraction; such treatments are currently recommended
by current clinical guidelines and variably incorporated in clinical practice [5,6]. A study using
data from the European Society of Cardiology’s (ESC) Heart Failure Long-Term Registry
(HF-LT-Registry, version 2013) found heterogeneity of treatments, most ineffective on hard
endpoints, for patients with acute HF, while drug treatments for patients with chronic HF can
be considered adherent to recommendations of current guidelines, even if dosing often
appears too parsimonious [7].
Research has highlighted the considerable differences in HF outcomes between different
countries [8,9]. Risk factors for HF outcomes have been studied mostly considering patient’s
clinical and socio-demographic characteristics. Age, medical history, comorbidities such as
pulmonary, liver, and kidney disease, are generally known to be related with a higher risk of
readmission [10] and mortality [11]. Other studies found socioeconomic factors, such as low
health literacy [12] and poor social support [13], are associated with higher all-cause mortality
among patients with HF.
Yet, hospital-level and country-level factors for HF outcomes remain largely unexplored.
One of the few studies that considered hospital characteristics as a predictor of hospital re-
admission found that discharge from hospitals with HF services is associated with lower
readmission at both 7 days and 30 days [10]. Recent work [14] studied income inequalities
within countries and HF outcomes, and found that greater inequality was associated with
worse HF outcomes. The structure and organization of healthcare systems and hospitals
may play an important role in the application of guideline recommendations in HF man-
agement and, as a consequence, in determining differences in patients’ outcomes [15].
There is a growing interest in studying the association between country-level inequality,
such as income, and various population health measures, but only a few studies have consid-
ered cardiovascular diseases.
This work aimed to fill this gap. Combining an international prospective cohort study, the
ESC Heart Failure Long Term (HF-LT) Registry, version 2016, and an international ESC Atlas
of cardiology, we created a unique set of data that enabled us to consider patient, hospital and
country characteristics at once and explore their association with the all-cause mortality of
patients with chronic HF. More specifically, we aimed to i) investigate between-country and
hospital variation in mortality rates among patients with chronic HF; ii) identify the character-
istics of patients, hospitals and countries associated with 1-year mortality of patients with
chronic HF.
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Methods
Design and setting
We combined information independently collected by two ESC projects, the prospective
cohort study called ESC HF-LT-Registry and the ESC Atlas of Cardiology, and created an
enhanced dataset to assess the concurrent association of patient’, hospital’ and country’s char-
acteristics with mortality in patients with chronic HF. Combining these databases, we were
able to gather information at three levels hierarchically ordered: patient, hospital and country.
The ESC HF-LT-Registry was launched in May 2011 to describe the clinical epidemiology
of outpatients and inpatients with HF and the diagnostic/therapeutic processes applied to
these patients across European and Mediterranean countries. The ESC HF-LT Registry also
includes a ‘Site Questionnaire’ where data on admission hospitals are collected, so providing
information on both patients and hospitals. A detailed description of the dataset (version
2016) is available elsewhere [11].
The ESC Atlas of Cardiology is a collection of cardiovascular data across 57 countries man-
aged by ESC to understand the structural determinants of cardiovascular disease outcomes. It
utilizes multiple data sources, including for example the World Health Organization and the
World Bank, to document risk factors, prevalence, and mortality of cardiovascular disease as
well as national economic indicators. It also includes an ESC-sponsored survey data of health
infrastructure and cardiovascular service provision provided by the national societies of the
ESC member countries [16,17]. Two Atlas editions have been issued and include indicators
collected between 2013 and 2017 [16,18]. We used both issues so to include a broader set of
indicators, available in the years in which patient and hospital data were collected, spanning
from 2013 to 2017.
This study complies with the Declaration of Helsinki. Participation in the ESC-HF-LT-R
had been approved by each local institutional review board in accordance with its country’s
legislation. National Coordinators were responsible for obtaining the approval of the local
review boards for this registry, if necessary. The Scientific Secretariat and Data Management
team distributed the relevant documents in English (protocol, case report form, consent form)
to the National Coordinators, who were responsible thereafter for their translation and adapta-
tion to local standards. The full names of the Institutions of each National Coordinator in
which the protocol was approved is reported in the supplementary file S1.1. All participants
provided written informed consent (see file S2). No data were collected before the patient
received detailed information and gave signed informed consent. No ethical approval was
needed for this specific retrospective analysis that was carried out under a signed agreement
between the Centre for Research on Health and Social Care (CERGAS) Bocconi University
and the European Society of Cardiology.
Study population
Outpatients aged over 18 years with chronic HF had been included in the HF LT Registry
since May 2011. We considered for the analysis all participants who underwent the 12-months
follow-up visit, which was performed to collect information on morbidity and mortality.
Clinical characteristics
At baseline visit, extensive information on patients’ characteristics were collected. We selected
those variables known to be related with HF outcomes [11]. These included demographic
characteristics (age and sex); information on cardiovascular risk factors collected at time of
enrolment (body mass index (BMI) treated as a five-category variable (<20, 20–24, 25–29, 30–
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34,>35), systolic blood pressure); clinical history (HF history, documentation of ischemic
heart disease, diabetes, atrial fibrillation, peripheral artery disease (PAD); chronic obstructive
pulmonary disease (COPD), chronic kidney dysfunction, left ventricular ejection fraction);
physical data included the New York Heart Association (NYHA) class, pulmonary rales, hepa-
tomegaly, peripheral oedema and third heart sound (S3 Gallop); information on medications
comprised the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor
blockers (ARBs), beta blockers prior and/or during outpatient visit and device therapy.
Outcome
The vital status of patients was recorded in the follow-up visit, which was expected to take
place approximately one year after the baseline visit. Owing to between-country differences in
the starting date of enrolment, there were varying follow-up times in the entire study group.
We considered all deaths recorded in the follow-up visit, and censored survival time at day 365
for those patients whose follow-up visit took place more than a year after their admission.
Hospital and country characteristics
The information on hospital’s characteristics that we extracted from the ESC-HF-LT Site
Questionnaire consisted in indicators of hospital’s services for HF: whether there are catheteri-
zation and electrophysiological laboratories, cardiology services in site available 24 hours,
units specifically dedicated to patients with HF and whether the hospital performs heart
transplants.
The country characteristics selected from the ESC Atlas of Cardiology included indicators
of socioeconomic status of a country: GDP per capita at purchasing price parity and the
inequality Gini index, which ranges from 0 (perfect income equality), to 100 (perfect inequal-
ity); indicators of health care resources including health expenditure per capita and as percent-
age of GDP; life expectancy at birth and number of deaths for cardiovascular diseases per
million inhabitants. We also classified countries based on their health care system and distin-
guished i) Beveridge-type (national health system) including Cyprus, Denmark, Greece, Italy,
Portugal and Spain; ii) Bismarck-type (social health insurance) including Austria, Bosnia &
Herzegovina, Bulgaria, Egypt, France, Israel, Lithuania, Serbia and Turkey, iii) Systems in tran-
sition (former Semaschko model) including Belarus, Czech Republic, Estonia, Hungary,
Poland, Slovakia and Slovenia [19].
Statistical analysis
Baseline characteristics were described using numbers and percentages for categorical data
and means and standard deviations for normally and nonnormally distributed continuous
variables.
To measure the association between 1-year all-cause mortality and selected risk factors, we
conducted a hierarchical analysis and selected piecewise exponential survival model (PWE)
and discrete time survival model [20], incorporating cluster-specific random effects (random
intercept) to account for within-cluster homogeneity in outcomes. In PWE model, the time
scale is divided into intervals and the hazard function is assumed to be constant within each
interval [21,22]. We split the survival time into four trimesters given that the hazard of death
among outpatients with chronic HF is stable over time and homogeneous within such time
segments [11]. From the PWE model we obtained Poisson regression coefficients, whose expo-
nential gave the incidence rate ratios that express the rate ratio change in mortality.
We considered the PWE model as the main model and run a discrete time survival model
as supplementary analysis (more details in the S1 Appendix). From the multilevel logistic
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model we assessed the degree of variation in mortality rates attributed to the country and hos-
pital levels (and not explained by the model), using the intraclass correlation coefficient (ICC),
as the calculation of the ICC from a multilevel Poisson model is not trivial [23,24].
We implemented several PWE model specifications in a stepwise fashion, considering the
clinical model with only patient’s characteristics as baseline and then investigating the additive
value of hospital and country characteristics adding each level-specific characteristics sepa-
rately (i.e., only patient’s characteristics, patient’s and hospital’s characteristics, patient’s and
country’s characteristics and full model). All statistical analyses were performed using Stata
(version 16).
Multiple imputation by chained equations was used to produce 20 imputed data sets to
minimize bias caused by missing data. Missing values were assumed to be random. Multiple
imputation provides unbiased estimates in the presence of missing data under the missing at
random assumption [25]. Details on the implementation of multiple imputation are provided
in the S1.2 appendix in S1 Appendix. A complete case analysis was also conducted.
Finally, as additional sensitivity analysis, to limit noises at hospital level due to small sample
size, we excluded from the sample hospitals with less than or up to 10 patients (37 hospitals
corresponding to 179 observations) and replicated the PWE full model.
Results
Sample selection
In total, 14 742 patients with chronic HF were included in the HF-LT Registry from 247 hospi-
tals, located in 37 countries, from 2011 to 2018, with most cases collected between 2011 and
2014. From this sample, we selected patients applying three criteria. First, we selected only
patients whose country was included in the ATLAS registry and whose participating hospital
submitted the ESC-HF-LT Site Questionnaire. Of the 37 nations included in the patient’s reg-
istry, 31 are included in ATLAS and 188 hospitals had site information available. Combining
these restrictions together, in order to have patients with information on both hospital and
country, we derived 11 347 observations collected from 165 hospitals across 27 countries. Sec-
ond, only patients whose vital status at 12 months was known were included, thus dropping
2027 cases with a sample of 9320 patients in 147 hospitals and 26 countries. Third, we dis-
charged observations from countries in which less than 30 patients were observed (thus drop-
ping 43 patients, in 5 hospitals, in 4 countries). Thus, the analytical cohort corresponded to
9277 patients from 142 hospitals in 22 countries. Fig 1 illustrates the sample selection process
through a STROBE flow chart and S1 Table in the S1 Appendix shows sample reduction by
country.
Baseline characteristics
Tables 1 and 2 illustrate, respectively, the patient and hospital characteristics. S2 Table in the
S1 Appendix illustrates descriptive statistics of patients for all available cases, before sample
selection (N = 14 742), to show descriptively whether the selected sample presents remarkable
differences compared to all patients enrolled. Selected cases presented very similar characteris-
tics compared to the original cohort of patients included in the registry. Country’s characteris-
tics are reported in S1.3 Table of the S1 Appendix.
Follow-up
Overall, the mean follow-up time was 342 days (sd 59.35, median 365, interquartile range
(IQR) 356–365). 620 deaths were registered, with an all-cause mortality rate per 100 person-
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year equal to 7.1 (95% confidence interval (CI) 6.6–7.7). Fig 2 presents crude mortality rates
and adjusted mortality rates with 95% CI for each country (we illustrate 95% CI of crude mor-
tality rates in S1 Fig in S1 Appendix to avoid overcrowd the graph). When we look at the crude
rates (green markers), remarkable differences in mortality rates across countries was observed,
although confidence intervals were wide for some countries (see S1 Fig in S1 Appendix).
Adjusted mortality rates were obtained from a Poisson model (using multiple imputation)
adjusting for patient’s age and sex and country (red markers) and all clinical and hospital vari-
ables (blue markers). The adjusted rates were often not statistically different, with wide CIs for
some countries.
Fig 3 shows descriptively the variation in mortality rates observed across hospitals and
countries. The units of analysis here are respectively hospitals (including only hospitals with at
least 3 patients, to reduce outliers) (box plot on the left) and countries (box plot on the right).
We observed a slightly larger variation in mortality rates between hospitals (median rate per
100-person year 7.8, IQR 5.2–12.4) compared to country (median 6.8, IQR 5.6–11.2). The
same statistics were produced for adjusted mortality rates (not shown), and results were rela-
tively similar for countries (median 7.0, IQR 5.7–8.8) and more variation was observed for
hospitals (median 7.7, IQR 3.0–13.8).
Mortality risk factors
Table 3 shows results from the PWE survival models (corresponding results based on complete
case analysis are available in S4 Table of the S1 Appendix). Results are reported as incidence
rate ratios. Estimates of incidence ratios (fixed effects) are consistent across multiple imputa-
tion and complete case analysis. Patient’s characteristics are associated with 1-year mortality as
expected: patients with older age (IRR = 1.03, 95% CI 1.02–1.04), suffering from diabetes
Fig 1. STROBE flow chart.
https://doi.org/10.1371/journal.pone.0250931.g001
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mellitus (1.37, 1.15–1.63), PAD (1.56, 1.27–1.92), renal dysfunction (1.82, 1.52–2.18), with
NYHA class III/IV (compared to I/II) (1.92, 1.60–2.30), having pulmonary or peripheral
Table 1. Baseline characteristics of the study population.
Variable Observed Missing values N (%)
Women 2613 (28.2) 1 (0.01)
Age in years. Mean (sd) 65 (13.2) 105 (1.1)
BMI, Kg/m2. Mean (sd) 28.1 (5.2) 125 (1.3)
BMI <20 62 (0.7)
BMI 20–24.9 2530 (27.3)
BMI 25–29.9 3731 (40.2)
BMI 30–34.9 1992 (21.5)
BMI>35 837 (9.0)
Systolic blood pressure, mmHg. Mean (sd) 123.7 (20.9) 29 (0.3)
Ischemic aetiology (%) 3993 (43) 6 (0.06)
Atrial fibrillation (%) 3465 (37.4) 9 (0.1)
Diabetes mellitus (%) 2968 (32) 5 (0.05)
Peripheral artery disease (%) 1158 (12.5) 31 (0.3)
Chronic obstructive pulmonary disease (%) 1319 (14.2) 18 (0.2)
Chronic kidney dysfunction (%) 1790 (19.3) 10 (0.1)
Implantable cardioverter defibrillator therapy (%) 2621 (28.3) 25 (0.3)
Left ventricular ejection fraction (%)
<40 5304 (57.2) 599 (6.5)
40–49 1663 (17.9)
> = 50 1711 (18.4)
New York Heart Association (NYHA) class III/IV (%) 2377 (25.6) 11 (0.1)
Pulmonary rales/hepatomegaly/peripheral oedema (%) 2866 (30.9) 18 (0.2)
Third heart sound (%) 527 (5.7) 39 (0.4)
Moderate or severe aortic stenosis (%) 294 (3.2) 1 336 (14.4)
Angiotensin-converting enzyme (ACE)-inhibitors (%) 6189 (66.7) 11 (0.1)
Angiotensin receptor blocker (ARB) (%) 2350 (25.3) 3 (0.03)
ACE inhibitors and/or ARBs (%) 8225 (88.7) 11 (0.1)
Beta Blockers (%) 8273 (89.2) 3 (0.03)
% are based on total number of patients (n = 9 277).
Values are number (%) of total sample (N = 9277) unless stated otherwise.
https://doi.org/10.1371/journal.pone.0250931.t001
Table 2. Hospitals’ baseline characteristics.
Variable Observed Missing N (%)
Catheterization laboratories (%) 101 (71.1) 18 (12.7)
Electrophysiological laboratories (%) 82 (57.8) 20 (14.1)
Cardiology Echocardiography service 24 hours on site (vs Regular hours) (%) 65 (47.8) 9 (6.3)
Cardiology Angiography/PCI service 24 hours on site (vs Regular hours) (%) 51 (35.9) 36 (25.4)
HF unit/clinic available for follow-up (%) 89 (62.7) 15 (10.6)
Heart transplant (%) 55 (38.7) 53 (37.3)
% are based on total number of hospitals (n = 142).
Values are number (%) of total sample (N = 142) unless stated otherwise.
https://doi.org/10.1371/journal.pone.0250931.t002
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congestion (1.85, 1.54–2.23) have higher mortality rate at one year; other patient’s characteris-
tics including left ventricular ejection fraction higher than 50 (0.78, 0.60–1.01), the use of ACE
inhibitors or ARBs (0.71, 0.57–0.87) appeared to be associated with lower mortality rates at 1
year. Higher BMI (e.g. IRR for BMI between 25 and 30 vs BMI<20 equal to 0.45, 0.21–0.95)
and higher systolic blood pressure (0.92, 0.90–0.95) also resulted associated with lower mortal-
ity, in line with previous findings [11]. In terms of hospital characteristics, only dedicated HF
clinic was significantly associated with a lower mortality rate, by around 40% (0.64, 0.46–0.89).
No other hospital characteristics were found to be related to 1-year mortality, neither the
selected country characteristics.
Fig 2. Crude mortality rates and adjusted mortality rates with 95% CI (vertical blue lines), by country sorted by
lowest to highest adjusted rate.
https://doi.org/10.1371/journal.pone.0250931.g002
Fig 3. Boxplot of the crude mortality rates per 100-person year across hospitals and countries.
https://doi.org/10.1371/journal.pone.0250931.g003
PLOS ONE Patient, hospital and country-level risk factors of mortality among patients with chronic heart failure
PLOS ONE | https://doi.org/10.1371/journal.pone.0250931 May 10, 2021 8 / 16







Patient + Hospital + Country
characteristics
IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI)
Clinical variables
Males (vs females) 1.23�� (1.01–1.51) 1.24�� (1.02–1.52) 1.23�� (1.01–1.51) 1.24�� (1.01–1.52)
Age in years 1.03��� (1.02–1.04) 1.0��� (1.02–1.04) 1.0��� (1.02–1.04) 1.03��� (1.02–1.04)
BMI (Kg/m2) (20–24.9) vs BMI<20 0.70 (0.335–1.47) 0.69 (0.33–1.45) 0.71 (0.34–1.48) 0.71 (0.34–1.48)
BMI (Kg/m2) (25–29.9) vs BMI<20 0.45�� (0.21–0.94) 0.44�� (0.21–0.92) 0.45�� (0.21–0.95) 0.45�� (0.21–0.95)
BMI (Kg/m2) (30–34.9) vs BMI<20 0.43�� (0.20–0.92) 0.42�� (0.20–0.89) 0.44�� (0.20–0.93) 0.43�� (0.20–0.93)
BMI (Kg/m2) (> = 35) vs BMI<20 0.43�� (0.19–0.95) 0.42�� (0.19–0.94) 0.44�� (0.20–0.97) 0.44�� (0.20–0.98)
Systolic blood pressure, mmHg 0.93��� (0.91–0.95) 0.92��� (0.90–0.95) 0.93��� (0.91–0.95) 0.92��� (0.90–0.95)
Ischemic etiology 1.10 (0.92–1.31) 1.11 (0.93–1.32) 1.10 (0.92–1.31) 1.11 (0.93–1.33)
Atrial Fibrillation history 1.10 (0.93–1.30) 1.11 (0.93–1.31) 1.10 (0.93–1.31) 1.11 (0.94–1.31)
Diabetes history 1.35��� (1.14–1.61) 1.36��� (1.14–1.62) 1.36��� (1.15–1.62) 1.37��� (1.15–1.63)
Peripheral artery disease 1.54��� (1.25–1.89) 1.56��� (1.27–1.91) 1.55��� (1.26–1.91) 1.56��� (1.27–1.92)
Chronic obstructive pulmonary disease 1.20� (0.98–1.47) 1.20� (0.98–1.46) 1.20� (0.98–1.47) 1.19� (0.98–1.46)
Chronic kidney dysfunction 1.80��� (1.50–2.15) 1.80��� (1.50–2.15) 1.81��� (1.52–2.17) 1.82��� (1.52–2.18)
Implantable cardioverter defibrillator therapy 0.96 (0.79–1.17) 0.97 (0.80–1.18) 0.99 (0.81–1.21) 0.99 (0.81–1.21)
New York Heart Association (NYHA) (III/IV vs I/II) 1.90��� (1.59–2.28) 1.90��� (1.59–2.28) 1.91��� (1.59–2.29) 1.92��� (1.60–2.30)
Peripheral oedema/pulmonary rale 1.87��� (1.56–2.24) 1.84��� (1.53–2.21) 1.84��� (1.53–2.22) 1.85��� (1.54–2.23)
s3gallop 1.22 (0.91–1.65) 1.19 (0.88–1.60) 1.17 (0.87–1.58) 1.17 (0.86–1.58)
Medication Angiotensin-converting enzyme (ACE)/
Angiotensin receptor blocker (ARB)
0.71��� (0.58–0.88) 0.71��� (0.57–0.88) 0.70��� (0.57–0.87) 0.71��� (0.57–0.87)
Medication beta blocker 0.82� (0.64–1.03) 0.83 (0.66–1.06) 0.84 (0.66–1.07) 0.85 (0.67–1.08)
Left ventricular ejection fraction (EF) 40–49 (vs EF<40) 0.83 (0.65–1.06) 0.83 (0.65–1.06) 0.83 (0.65–1.06) 0.83 (0.65–1.06)
EF> = 50 (vs EF<40) 0.76�� (0.59–0.98) 0.77�� (0.60–0.99) 0.77�� (0.60–0.99) 0.78� (0.60–1.01)
Interval 90–180 days 1.16 (0.93–1.46) 1.16 (0.93–1.46) 1.16 (0.93–1.46) 1.17 (0.93–1.46)
180–270 days 1.26�� (1.01–1.58) 1.26�� (1.01–1.58) 1.26�� (1.01–1.58) 1.26�� (1.007–1.58)
270–365 days 1.30�� (1.03–1.63) 1.30�� (1.03–1.63) 1.29�� (1.03–1.63) 1.30�� (1.03–1.63)
Hospital’s characteristics
Catheterisation lab 1.30 (0.86–1.98) 1.37 (0.88–2.13)
Electrophysiological lab 0.96 (0.66–1.40) 0.94 (0.64–1.40)
Cardiology Echocardiography service 24 hrs on site (vs
Regular hours)
1.01 (0.76–1.34) 0.98 (0.72–1.33)
Cardiology Angiography/PCI service 24 hrs on site (vs
Regular hours)
0.93 (0.69–1.26) 0.95 (0.70–1.31)
Heart failure unit 0.62��� (0.46–0.83) 0.64��� (0.46–0.89)
Heart transplantation 0.87 (0.64–1.18) 0.84 (0.61–1.16)
Country’s characteristics
Gross Domestic Product (GDP) (in thousands $) 0.99 (0.93–1.05) 1.00 (0.94–1.07)
Life Expectancy at birth (years) 0.93 (0.77–1.13) 0.94 (0.77–1.14)
Total health expenditure (% of GDP) 1.10 (0.94–1.27) 1.11 (0.94–1.30)
Gini Index 3.33 (0.001–12,146.57) 17.83 (0.01–59,194.69)
Health expenditure per capita (PPP) (in thousands $) 1.112 (0.719–1.722) 1.12 (0.72–1.74)
Cardiovascular disease deaths per million inhabitants
(in thousands per year)
0.997 (0.803–1.238) 1.053 (0.849–1.307)
Health system Bismarck (vs Beveridge) 1.213 (0.548–2.682) 1.138 (0.515–2.516)
Health system Semashko (vs Beveridge) 1.090 (0.424–2.804) 0.883 (0.349–2.232)
Random Effects
(Continued)
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Looking at the variance component (random effects, bottom of Table 3), variation in mor-
tality due to differences between countries was negligible across all model specifications
(1.83e-06 in the model adjusted for all selected variables), and variation between hospitals was
evident in each model specification, and it reduced by about 20% following adjustment for
hospital-level and country-level variables (0.456 when accounting only for patient’s character-
istics, 0.372 adjusting for all-level variables).
Comparing these results with those obtained from complete case analysis (S4 Table in S1
Appendix), we observed that between-hospital variance was smaller in complete case analysis
(0.030, 95% CI 4.95E-06–12.622 in the model adjusted for all-level variables) compared to
results obtained using multiple imputation, where more observations (patients, hospitals,
countries) were included in the model. This may suggest a selection of more homogeneous
hospitals in the complete case analysis and a consequent reduction of variation between cen-
tres. Between-country variance was unstable across model specifications in complete case anal-
ysis and generally lower than between-hospital variance.
Results were replicated within a discrete time survival model (see S1 Appendix), for both
multiple imputation and complete case analysis (S5 Table in S1 Appendix). Estimates are
reported as odds ratios and hence not directly comparable, but significance, direction and
magnitude of results are consistent across model specifications, comparing multiple imputa-
tion and complete case analyses respectively. From the multilevel logistic regression model, we
found that after case mix adjustment the mortality risk of patients in the same country was
basically uncorrelated (ICC 9.156e-07), whilst mortality risk for patients within the same hos-
pital had a higher correlation (ICC = 0.084).
Discussion
Principal findings
In this international cohort of 9277 participants from 22 countries which pooled retrospective
data from a bespoke patient and hospital datasets and ATLAS of cardiology, there was evi-
dence that clinical variables, shown by different studies to be associated with mortality of
patients with chronic HF, have a significant role in the association with HF outcomes also after








Patient + Hospital + Country
characteristics
IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI)
Country variance (s.e.)§ (95% CI) 2.28e-06 (.03769)
(0.000 -.)
5.42e07 (.3467) (0.000 -.) 4.97e-07 (.0752) (0.000
-.)
1.83e-06 (.5788) (0.000 -.)
Hospital variance (95% CI) 0.456 (0.322–0.646) 0.393 (0.263–0.586) 0.406 (0.278–0.594) 0.372 (0.247–0.561)
Observations 35,812 35,812 35,812 35,812
Number of hospitals 142 142 142 142
Number of countries 22 22 22 22




§ s.e. reported given 95% CI was not computable.
https://doi.org/10.1371/journal.pone.0250931.t003
PLOS ONE Patient, hospital and country-level risk factors of mortality among patients with chronic heart failure
PLOS ONE | https://doi.org/10.1371/journal.pone.0250931 May 10, 2021 10 / 16
The 1-year all-cause mortality rate per 100 person-year was equal to 7.1 (95% CI 6.6–7.7),
largely varying across countries and hospitals. We identified factors related to hospital and
country variations and accounting for these variables, we found almost null between-country
variance and higher between-hospital variance. We explored the additive value of hospital and
country characteristics to clinical characteristics and it emerged that the presence of dedicated
HF clinics was the strongest predictor of all country and hospital specific variables. This repre-
sents a key contribution of this work, as discussed below.
Comparison with other studies
Our study supports the set of prognostic clinical variables already emerged as statistically sig-
nificant in other studies, [26–30] but with the uniqueness to have included in the adjusted
model hospital and country variables. This observation reinforces the relevance of the clinical
characteristics of the patients to be considered for prognostic purposes, irrespective of both
borders and typology of hospitals.
Among hospital characteristics, the availability of a dedicated HF clinic appeared to be
independently associated with a lower risk of all-cause death. The complexity of the manage-
ment of patients with HF, generally old, with multiple comorbidities, with the need to assume
daily several drugs needs the activity and the expertise of several health professional. The ideal
setting for establishing all the diagnostic and therapeutic strategies recommended for these
complex patients seems to be the HF clinic where the possibility to have an easy access to
nurses and physicians with expertise in HF and in the treatment of the most frequent comor-
bidities can be assured [31]. The multi-professional model of care provided by a dedicated HF
clinic was demonstrated to be able to improve adherence to treatments recommended by cur-
rent guidelines and to significantly reduce the need of hospital admissions and mortality [32–
35]. Our study confirms the relevant role of these HF dedicated hospital structures in a multi-
national setting and even after the adjustment for the clinical, hospital and country
characteristics.
To interpret the lack of association between country level factors and mortality among
patients with chronic HF as well as the low country variation, it is useful to put the results in a
global perspective. Among European high-income countries, that compose the majority of our
sample, the socio-economical differences may not be strong enough to impact measurably on
survival. By contrast in the low and low-middle income countries, it has been found that two
third of attributable risk is carried by socio-economic factors [36,37]. A study focused on low-
middle income countries found marked regional differences in mortality in patients with HF
that persisted even after multivariable adjustment for cardiac and non-cardiac factors [8];
while a research that considered both middle and high income countries, found that after
accounting for clinical characteristics of patients only Latin America and Pacific Asia pre-
sented higher mortality rates compared to the other sub-continents [9].
The results of our work shed further light in the literature on geographic variation in HF
outcomes, because it focuses on European and non-European Mediterranean countries con-
sidered individually (rather than as subcontinental clusters) and especially because it considers
also risk factors measured at hospital and country level, not only clinical variables.
Strengths and limitations of study
The main strength of this research comes from the use of multisource linked data that allowed
us to explore the concurrent role of clinical conditions of participants and hospital’s and coun-
try’s characteristics on the outcomes of patients with chronic HF. The determinants of out-
comes of patients with HF have been evaluated by several groups but, in most cases, only
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considering clinical variables. This study built on existing literature and expanded current
knowledge by taking into consideration other relevant aspects that could affect the clinical
course of this population of patients, the hospital characteristics and some variables describing
the health care and socioeconomic context in which patients live and received treatments.
The fact that the study design had a mandatory follow-up visit at 12 months to collect infor-
mation on morbidity and mortality represented a strength and unique opportunity to study
survival with a relatively uniform follow-up time across countries. At the same time, however,
we had no information on the time course of patients’ HF over this period. Not being able to
monitor the HF progress, little we know on possible precipitating factors that may lead to
decompensation during the follow-up, and that are known to be different in young and older
patients [38]. Nevertheless, we accounted for patients’ clinical and medical history, partly
accounting for those factors that may act as precipitators in the HF time course.
This study suffers from some specific limitations that should be mentioned. The first one
concerns sample selection and generalizability of our findings. The National Cardiac Societies
which participated in the ESC registry were requested to appoint a national coordinator
responsible for creating a network of centres and to manage it in connection with the EORP
team. However, while a central data quality control was systematic and accurate, a systematic
peripheral auditing was not possible, thereby the compliance to the protocol recommendations
was not individually verified. This implies a threefold limitation: not all countries contributed
to the questionnaire equally in terms of i) number of patients submitted, ii) type of patients i.e.
case severity mix and iii) types of participating hospitals. Moreover, the fact that the selection
of hospitals was made by ESC guarantees a recognized quality of participating hospitals, but at
the same time entails a possible selection bias. This altered how representative a country’s con-
tribution was to the registry and therefore when we referred to each country, we in fact
referred to its contribution to the registry. This contribution varied between countries leading
to uneven representation of countries.
Several observations were discharged because no information on the participating hospital
characteristics was available affecting the generalizability of results. Within the sample selected,
item nonresponse was addressed using multiple imputation. Compared to complete case anal-
ysis, fixed effects results (coefficients estimate) were similar, while the random part, capturing
the country and hospital variation, revealed higher between-hospital variability when using all
selected observations. This warns on the risk of selection bias, as highlighted among the study
limitations, because responding centres might represent a subsample of homogeneous hospi-
tals, hence not representative of all enrolled centres. Such limitation must be carefully consid-
ered to interpret the key finding of this study on the protective effect of the presence of a HF
clinic: for 30% of the centres that took part to the registry, information on HF clinics (n = 76
out of 247) was missing; among those selected for this study 10% did not report this informa-
tion (15 out of 142), but we were able to impute it and the evidence of a strong association
with mortality was found both using multiple imputation and complete case analysis. Further
research is needed to confirm the generalizability of our findings. Finally, we also performed a
sensitivity analysis dropping observations from hospitals with less than or up to 10 patients to
reduce noises due to small sample size of clusters and obtained results (S6 Table in S1 Appen-
dix) very similar to those presented in Table 3 (column 4).
Conclusions and policy implications
A unique contribution of this study is that it considered risk factors for HF outcomes acting at
three levels simultaneously: clinical, hospital and country. Results confirmed that the clinical
variables known to be associated with outcomes of patients with HF remained significantly
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associated with mortality even after adjustment for hospital and country characteristics. The
finding that the presence, at hospital level, of dedicated HF clinics was significantly associated
with a lower mortality rate suggests that this type of health care service can probably assure a
more appropriate treatment of patients and a higher adherence to the recommendations of the
current ESC guidelines, which recommend that patients with HF are enrolled in a multidisci-
plinary care management programmes. [3] Such an approach has been found reducing HF
hospitalization and mortality in patients discharged from the hospital. [32,33] Our work con-
tributes to this discussion providing empirical evidence on the protective effect of HF clinics
to support this statement and may be used to strengthen this statement in future guidelines.
The ESC guidelines suggest that “content and structure of HF management programmes
may vary in different countries and health care settings”. Due to the data limitations we cannot
provide further insight on country variability in this matter, and further research is needed to
intersect the role of hospital facilities with country’s health care settings.
The other contribution of this research pertains to the assessment of country and hospital
variation in mortality. The finding that after the full adjustment for clinical, hospital and coun-
try variables, there appeared to be some variation only at hospital level suggests that, in a cardi-
ology setting of ESC member countries, presumably there remain a certain level of variability
in the adoption of guideline recommendations, contributing to inequalities in patients’ out-
comes. The timely and full adherence to clinical practice guidelines is fundamental for assuring
high level of care. Efforts should be placed to guarantee their applications across and within
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